# Molecular determinants of acute kidney injury

**Authors:** Holger Husi, Christin Human

PMC · DOI: 10.5249/jivr.v7i2.615 · Journal of Injury and Violence Research · 2015-07-01

## TL;DR

This paper explores the molecular pathways involved in acute kidney injury and how they could be targeted for treatment.

## Contribution

The paper provides a comprehensive overview of molecular pathways in AKI and their potential for pharmacological intervention.

## Key findings

- The RAAS axis is a common element in AKI progression, triggering immune responses via the NFB pathway.
- TNF α and TGF β signaling cascades are intricately linked with AKI induction and progression.
- The glutamatergic axis, typically associated with the neurological system, is a major contributor to AKI.

## Abstract

Acute kidney injury (AKI) is a condition that leads to a rapid deterioration of renal function associated with impairment to maintain electrolyte and acid balance, and, if left untreated, ultimately irreversible kidney damage and renal necrosis. There are a number of causes that can trigger AKI, ranging from underlying conditions as well as trauma and surgery. Specifically, the global rise in surgical procedures led to a substantial increase of AKI incidence rates, which in turn impacts on mortality rates, quality of life and economic costs to the healthcare system. However, no effective therapy for AKI exists. Current approaches, such as pharmacological intervention, help in alleviating symptoms in slowing down the progression, but do not prevent or reverse AKI-induced organ damage.

An in-depth understanding of the molecular machinery involved in and modulated by AKI induction and progression is necessary to specifically pharmacologically target key molecules. A major hurdle to devise a successful strategy is the multifactorial and complex nature of the disorder itself, whereby the activation of a number of seemingly independent molecular pathways in the kidney leads to apoptotic and necrotic events.

The renin-angiotensin-aldosterone-system (RAAS) axis appears to be a common element, leading to downstream events such as triggers of immune responses via the NFB pathway. Other pathways intricately linked with AKI-induction and progression are the tumor necrosis factor alpha (TNF α) and transforming growth factor beta (TGF β) signaling cascades, as well as a number of other modulators. Surprisingly, it has been shown that the involvement of the glutamatergic axis, believed to be mainly a component of the neurological system, is also a major contributor.

Here we address the current understanding of the molecular pathways evoked in AKI, their interplay, and the potential to pharmacologically intervene in the effective prevention and/or progression of AKI.

## Linked entities

- **Proteins:** TNF (tumor necrosis factor), TGFB1 (transforming growth factor beta 1)
- **Diseases:** acute kidney injury (MONDO:0002492)

## Full-text entities

- **Genes:** CA2 (carbonic anhydrase 2) [NCBI Gene 760] {aka CA-II, CAC, CAII, Car2, HEL-76, HEL-S-282}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, B2M (beta-2-microglobulin) [NCBI Gene 567] {aka AMYLD6, IMD43, MHC1D4}, GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932], NOS2 (nitric oxide synthase 2) [NCBI Gene 4843] {aka HEP-NOS, INOS, NOS, NOS2A}, AZGP1 (alpha-2-glycoprotein 1, zinc-binding) [NCBI Gene 563] {aka ZA2G, ZAG}, AGT (angiotensinogen) [NCBI Gene 183] {aka ANHU, SERPINA8, hFLT1}, SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714] {aka ASV, SRC1, THC6, c-SRC, p60-Src}, CST3 (cystatin C) [NCBI Gene 1471] {aka ADLDWA, ARMD11, HEL-S-2}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, GRM1 (glutamate metabotropic receptor 1) [NCBI Gene 2911] {aka GPRC1A, MGLU1, MGLUR1, PPP1R85, SCA44, SCAR13}, CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, OGA (O-GlcNAcase) [NCBI Gene 10724] {aka MEA5, MGEA5, NCOAT}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, NFKB2 (nuclear factor kappa B subunit 2) [NCBI Gene 4791] {aka CVID10, H2TF1, LYT-10, LYT10, NF-kB2, p100}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}, PRRT2 (proline rich transmembrane protein 2) [NCBI Gene 112476] {aka BFIC2, BFIS2, DSPB3, DYT10, EKD1, FICCA}, F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}, RPS6KA5 (ribosomal protein S6 kinase A5) [NCBI Gene 9252] {aka MSK1, MSPK1, RLPK}, PFKL (phosphofructokinase, liver type) [NCBI Gene 5211] {aka ATP-PFK, PFK-B, PFK-L}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, NAGLU (N-acetyl-alpha-glucosaminidase) [NCBI Gene 4669] {aka CMT2V, MPS-IIIB, MPS3B, NAG, UFHSD}, SPHK1 (sphingosine kinase 1) [NCBI Gene 8877] {aka SPHK}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, HLA-G (major histocompatibility complex, class I, G) [NCBI Gene 3135] {aka MHC-G}, PARG (poly(ADP-ribose) glycohydrolase) [NCBI Gene 8505] {aka PARG99}, NR3C2 (nuclear receptor subfamily 3 group C member 2) [NCBI Gene 4306] {aka MCR, MLR, MR, NR3C2VIT}, DAPK1 (death associated protein kinase 1) [NCBI Gene 1612] {aka DAPK, ROCO3}, PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, CDC42 (cell division cycle 42) [NCBI Gene 998] {aka CDC42Hs, G25K, TKS}, CAMK2G (calcium/calmodulin dependent protein kinase II gamma) [NCBI Gene 818] {aka CAMK, CAMK-II, CAMKG, MRD59}, LCN2 (lipocalin 2) [NCBI Gene 3934] {aka 24p3, MSFI, NGAL, p25}, MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313] {aka CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1}, HAVCR1 (hepatitis A virus cellular receptor 1) [NCBI Gene 26762] {aka CD365, HAVCR, HAVCR-1, KIM-1, KIM1, TIM}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, NPY4R (neuropeptide Y receptor Y4) [NCBI Gene 5540] {aka NPY4-R, PP1, PPYR1, Y4}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, IL11 (interleukin 11) [NCBI Gene 3589] {aka AGIF, IL-11}, ITPR3 (inositol 1,4,5-trisphosphate receptor type 3) [NCBI Gene 3710] {aka CMT1J, IMD132, IMD133, IP3R, IP3R-3, IP3R3}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, FABP1 (fatty acid binding protein 1) [NCBI Gene 2168] {aka FABPL, L-FABP}, SLC36A1 (solute carrier family 36 member 1) [NCBI Gene 206358] {aka Dct1, LYAAT1, PAT1, TRAMD3}, PTK2 (protein tyrosine kinase 2) [NCBI Gene 5747] {aka FADK, FADK 1, FAK, FAK1, FRNK, PPP1R71}
- **Diseases:** renal necrosis (MESH:D007673), Hyperglycemia (MESH:D006943), liver disease (MESH:D008107), Hypotension (MESH:D007022), Pelvic malignancy (MESH:D010386), cancer (MESH:D009369), renal vein thrombosis (MESH:D012170), sepsis (MESH:D018805), ischaemia (MESH:D007511), Edema (MESH:D004487), burns (MESH:D002056), organ damage (MESH:D000092124), hepatorenal syndrome (MESH:D006530), kidney damage (MESH:D007674), cirrhosis (MESH:D005355), vomiting (MESH:D014839), loss of kidney function (MESH:D007680), hyperthyroidism (MESH:D006980), metabolic acidosis (MESH:D000138), Necrosis (MESH:D009336), mitochondrial damage (MESH:D028361), uremia (MESH:D014511), malignant hypertension (MESH:D006974), rheumatoid arthritis (MESH:D001172), injury (MESH:D014947), Papillary necrosis (MESH:D007681), abdominal aortic aneurysm (MESH:D017544), polyarteritis nodosa (MESH:D010488), Renal hypoperfusion (MESH:D006030), Acute Kidney Injury (MESH:D058186), Hypertension (MESH:D006973), hypoxic (MESH:D002534), Post-renal - Urinary tract obstructions (MESH:C563661), thrombocytopenia (MESH:D013921), cardiogenic shock (MESH:D012770), Cardiovascular (MESH:D002318), Diabetes (MESH:D003920), nephrotic syndrome (MESH:D009404), renal artery stenosis (MESH:D012078), retroperitoneal fibrosis (MESH:D012185), obese (MESH:D009765), blood loss (MESH:D016063), Inflammation (MESH:D007249), prostatic hypertrophy or malignancy (MESH:D011470), interstitial nephritis (MESH:D009395), urological obstruction (MESH:D014570), tubular dysfunction (MESH:D005198), arrhythmias (MESH:D001145), pressure (MESH:D003668), chronic kidney disease (MESH:D051436), damage (MESH:D020263), Vascular disease (MESH:D014652), Injury, Failure, Loss, End stage kidney disease (MESH:D051437), extra (MESH:D000092225), apoptosis (MESH:D065703), renal cell loss (MESH:D002292), tissue (MESH:D017695), hemolytic uraemic syndrome (MESH:D006463), Eclampsia (MESH:D004461), shock (MESH:D012769)
- **Chemicals:** S1P (MESH:C060506), Isoflurane (MESH:D007530), AA (MESH:D016718), Ca+2 (-), heavy metals (MESH:D019216), Cl- (MESH:D002713), urea (MESH:D014508), cortisol (MESH:D006854), ATP (MESH:D000255), JTE013 (MESH:C471998), urea nitrogen (MESH:C530477), Hypoxanthine (MESH:D019271), hydrogen peroxide (MESH:D006861), glutamate (MESH:D018698), glucose (MESH:D005947), cisplatin (MESH:D002945), spermidine (MESH:D013095), NAD (MESH:D009243), potassium (MESH:D011188), Na+ (MESH:D012964), fructose 1,6-bisphosphate (MESH:C029063), ROS (MESH:D017382), aminoglycosides (MESH:D000617), creatinine (MESH:D003404), calcium (MESH:D002118), cycloheximide (MESH:D003513), NO (MESH:D009569), TDZD-8 (MESH:C494356), luminal (MESH:D010634), cholesterol (MESH:D002784), DAG (MESH:D004075), sphingosine (MESH:D013110), 20-HETE (MESH:C055987),  (MESH:D014409),  (MESH:D015291),  (MESH:D015415)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC4522318/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC4522318/full.md

## References

105 references — full list in the complete paper: https://tomesphere.com/paper/PMC4522318/full.md

---
Source: https://tomesphere.com/paper/PMC4522318